Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying

Published 08/12/2023, 13:50
Updated 08/12/2023, 15:10
© Reuters.  SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
SILC
-
QNCX
-
UPST
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

SHF Holdings

  • The Trade: SHF Holdings, Inc. (NASDAQ: SHFS) Chief Legal Officer Donald Emmi acquired a total of 66,000 shares an average price of $0.87. To acquire these shares, it cost around $57,420. The company’s CEO also bought 20,000 shares of the company.
  • What’s Happening: On Nov. 14, SHF Hldgs posted a loss for the third quarter.
  • What SHF Holdings Does: SHF Holdings Inc is a financial services provider to cannabis-related businesses.
Quince Therapeutics
  • The Trade: Quince Therapeutics, Inc. (NASDAQ: QNCX) Director David Lamond acquired a total of 57,369 shares at an average price of $1.01. To acquire these shares, it cost around $58,134.
  • What’s Happening: On Oct. 23, Quince Therapeutics announced the successful completion of its acquisition of EryDel S.p.A.
  • What Quince Therapeutics Does: Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases.

Silo Pharma

  • The Trade: Silo Pharma, Inc. (NASDAQ: SILO) President and CEO Eric Weisblum acquired a total of 1,000 shares at an average price of $1.38. The insider spent around $1,376 to buy those shares.
  • What’s Happening: On Nov. 21, Silo Pharma entered into exclusive license agreement with Medspray Pharma BV for intranasal technology used in SPC-15 treatment for PTSD.
  • What Silo Pharma Does: SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Upexi
  • The Trade: Upexi, Inc. (NASDAQ: UPXI) CEO Allan Marshall acquired a total of 90,001 shares at an average price of $0.94. The insider spent around $84,952 to buy those shares.
  • What’s Happening: On Nov. 20, Upexi posted a wider-than-expected quarterly loss.
  • What Upexi Does: Upexi Inc is an innovator in aggregation, accelerating Amazon and eCommerce businesses by combining consumer data and vertical integration to scale brands in multiple industries, while lowering costs with a growing distribution network.

Don’t forget to check out our premarket coverage here

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.